Muzeyyen Aslaner Ak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Muzeyyen Aslaner Ak has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
- Şehmus Ertop
Bülent Ecevit University
8 shared publications - Birsen Sahip Yesiralioglu
Bülent Ecevit University
6 shared publications - Birol Guvenc
ÇUKUROVA ÜNİVERSİTESİ, TIP FAKÜLTESİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, İÇ HASTALIKLARI ANABİLİM DALI, HEMATOLOJİ BİLİM DALI
4 shared publications - Ayfer Gedük
Faculty of Medicine Hematology Clinic, Kocaeli University, Kocaeli 41380, Türkiye
3 shared publications - İbrahim Halil Acar
ÇUKUROVA ÜNİVERSİTESİ, TIP FAKÜLTESİ
3 shared publications - Ali Doğan
Van Yüzüncü Yıl University, Faculty of Medicine, Department of Hematology, Van, Türkiye
2 shared publications
Latest Publications
- Open Access
- 30 June 2025
- Published by Ağrı İbrahim Çeçen University Faculty of Medicine in Ağrı Tıp Fakültesi Dergisi
- Vol. 3 (2) , 68-73
Evaluation of cholesterol levels in hematological malignancies
Aim: The studies show that dyslipidemia may pose a risk factor for the emergence of malignancies. The study evaluates the lipid parameters of patients diagnosed with hematologic malignancy during diagnosis, investigating their relationship with hematologic malignancy and the parameters' effects on remission and its duration. Material and Method: The study included 68 male and 63 female patients with a mean age of 66.1±13.9 years. HDL, LDL, TG, and their TC levels diagnosed with hematologic malignancies due to peripheral smear, bone marrow, and lymph node biopsy between 2015 and 2021 were retrospectively analyzed. According to the statistically analyzed association data between cholesterol levels and hematologic malignancies, p<0.05 was considered significant. Results: Out of all the individuals studied, 12.9% were diagnosed with acute leukemia, 25.1% had chronic leukemia, 32% were diagnosed with multiple myeloma, and 29.7% had lymphoma. Among the patients, 40.5% were in remission, while 59.5% were in relapse clinics. Patients in remission had significantly lower HDL levels compared to those in relapse. However, there was no significant difference between the two groups for LDL, triglycerides, and TC levels. Conclusion: Some studies show that low HDL levels increase the risk of developing hematologic malignancy, low HDL levels decrease survival in patients with hematologic malignancy, and high HDL levels decrease the risk of recurrence development. Although no correlation was found between hematologic malignancy diagnosis groups and lipid levels, this study shows that HDL levels were higher in relapse clinic patients than in the remission group.
- 30 June 2025
- Published by Ağrı İbrahim Çeçen University Faculty of Medicine in Ağrı Tıp Fakültesi Dergisi
- Vol. 3 (2) , 68-73
Open AccessEvaluation of cholesterol levels in hematological malignancies
Aim: The studies show that dyslipidemia may pose a risk factor for the emergence of malignancies. The study evaluates the lipid parameters of patients diagnosed with hematologic malignancy during diagnosis, investigating their relationship with hematologic malignancy and the parameters' effects on remission and its duration. Material and Method: The study included 68 male and 63 female patients with a mean age of 66.1±13.9 years. HDL, LDL, TG, and their TC levels diagnosed with hematologic malignancies due to peripheral smear, bone marrow, and lymph node biopsy between 2015 and 2021 were retrospectively analyzed. According to the statistically analyzed association data between cholesterol levels and hematologic malignancies, p<0.05 was considered significant. Results: Out of all the individuals studied, 12.9% were diagnosed with acute leukemia, 25.1% had chronic leukemia, 32% were diagnosed with multiple myeloma, and 29.7% had lymphoma. Among the patients, 40.5% were in remission, while 59.5% were in relapse clinics. Patients in remission had significantly lower HDL levels compared to those in relapse. However, there was no significant difference between the two groups for LDL, triglycerides, and TC levels. Conclusion: Some studies show that low HDL levels increase the risk of developing hematologic malignancy, low HDL levels decrease survival in patients with hematologic malignancy, and high HDL levels decrease the risk of recurrence development. Although no correlation was found between hematologic malignancy diagnosis groups and lipid levels, this study shows that HDL levels were higher in relapse clinic patients than in the remission group.
- Open Access
- 1 January 2025
- Published by Wiley in Dermatologic Therapy
- Vol. 2025 (1)
Dermatology Consultations From the Hematology Department: A Retrospective Single‐Center Analysis
Introduction: Hematological disorders are often associated with dermatological conditions due to immune dysregulation and the use of polypharmacy. Such dermatological manifestations have the potential to impair quality of life and may also result in morbidity and mortality. Furthermore, in some instances, it may be necessary to modify the treatment regimen. Methods: This study retrospectively evaluated dermatological consultations for patients in a hematology clinic, assessing clinical and demographic data, dermatological diagnoses, and the effects on hematological treatment and prognosis. Results: The data from 434 consultations involving 304 patients were subjected to analysis, with the most prevalent hematological diagnoses being acute myeloid leukemia, multiple myeloma, and myelodysplastic syndrome. The majority of consultations (70.7%, n = 307) were inpatient, while the remainder were outpatient. The most frequently observed dermatological conditions were infections (37.3%) and drug reactions (15.7%). In 39.4% ( n = 171) of cases, dermatological findings led to modifications in systemic treatment, primarily due to infections and drug reactions. Among these patients, 19 required modifications to their hematological treatment regimen. A diagnosis was reached through clinical examination in 74.9% of patients. In other cases, additional diagnostic procedures were necessary, including dermoscopy, histopathology, and microbial examination. The in‐hospital mortality rate was 2.3% ( n = 7). Only one death was directly associated with a dermatological condition: toxic epidermal necrolysis in a patient receiving brentuximab vedotin. Conclusion: The results of this study highlight the importance of dermatological assessment in patients with hematological conditions. It is also crucial for clinicians to be more aware of the potential dermatological manifestations, including infections and drug reactions, that may occur in these patients.
- 1 January 2025
- Published by Wiley in Dermatologic Therapy
- Vol. 2025 (1)
Open AccessDermatology Consultations From the Hematology Department: A Retrospective Single‐Center Analysis
Introduction: Hematological disorders are often associated with dermatological conditions due to immune dysregulation and the use of polypharmacy. Such dermatological manifestations have the potential to impair quality of life and may also result in morbidity and mortality. Furthermore, in some instances, it may be necessary to modify the treatment regimen. Methods: This study retrospectively evaluated dermatological consultations for patients in a hematology clinic, assessing clinical and demographic data, dermatological diagnoses, and the effects on hematological treatment and prognosis. Results: The data from 434 consultations involving 304 patients were subjected to analysis, with the most prevalent hematological diagnoses being acute myeloid leukemia, multiple myeloma, and myelodysplastic syndrome. The majority of consultations (70.7%, n = 307) were inpatient, while the remainder were outpatient. The most frequently observed dermatological conditions were infections (37.3%) and drug reactions (15.7%). In 39.4% ( n = 171) of cases, dermatological findings led to modifications in systemic treatment, primarily due to infections and drug reactions. Among these patients, 19 required modifications to their hematological treatment regimen. A diagnosis was reached through clinical examination in 74.9% of patients. In other cases, additional diagnostic procedures were necessary, including dermoscopy, histopathology, and microbial examination. The in‐hospital mortality rate was 2.3% ( n = 7). Only one death was directly associated with a dermatological condition: toxic epidermal necrolysis in a patient receiving brentuximab vedotin. Conclusion: The results of this study highlight the importance of dermatological assessment in patients with hematological conditions. It is also crucial for clinicians to be more aware of the potential dermatological manifestations, including infections and drug reactions, that may occur in these patients.
- Open Access
Multicentral Retrospective Analysis of Venetoclax-Based Treatments in AML and MDS: A Real-World Study by the Turkish Hematology Network Group
Background and Objectives: Acute myeloid leukemia and myelodysplastic syndrome are both clonal hematologic malignancies that primarily affect older adults. Current treatments for AML/MDS are both limited in number and efficacy. This study aims to evaluate venetoclax-based therapies in AML/MDS, focusing on overall survival and recurrence-free survival rates, and to expand real-world data on its use. Materials and Methods: Clinical and laboratory data on patients with AML/MDS aged 18≥ treated with venetoclax between January 2019 and July 2022 were included. Survival analysis was calculated based on the period from 2019 to December 2023. Results: A total of 161 AML and 40 patients with MDS were included. The median age was 63.53 ± 15.30 years for AML and 70.12 ± 10.21 years for MDS. In both groups, over 55% are male. A total of 77.6% of patients with AML and 75% of patients with MDS received treatment prior to venetoclax. Venetoclax was administered in combination with azacitidine to 84.5% of AML and 67.5% of MDS. The relapse rate in AML is approximately 15%. Overall, the 2-year survival rate is 46% and 18.73 months. The overall CR/CRi rate for patients with AML is 49.1%, while for patients with MDS, it is 50%. The 2-year survival rate for patients with MDS is 52.7%. The 2-year RFS rate was 75.5% for AML and 90.9% for MDS. The relapse rate in AML is approximately 15%. The percentage of adverse events leading to treatment discontinuation among those with grade 3–4 toxicity is low; 26.7% for AML (n = 43) and 15% for MDS (n = 6). Conclusions: Our real-world data demonstrate that venetoclax has the potential to improve overall survival rates when used in combination with HMAs and supports its use in patients with AML/MDS.
Open AccessMulticentral Retrospective Analysis of Venetoclax-Based Treatments in AML and MDS: A Real-World Study by the Turkish Hematology Network Group
Background and Objectives: Acute myeloid leukemia and myelodysplastic syndrome are both clonal hematologic malignancies that primarily affect older adults. Current treatments for AML/MDS are both limited in number and efficacy. This study aims to evaluate venetoclax-based therapies in AML/MDS, focusing on overall survival and recurrence-free survival rates, and to expand real-world data on its use. Materials and Methods: Clinical and laboratory data on patients with AML/MDS aged 18≥ treated with venetoclax between January 2019 and July 2022 were included. Survival analysis was calculated based on the period from 2019 to December 2023. Results: A total of 161 AML and 40 patients with MDS were included. The median age was 63.53 ± 15.30 years for AML and 70.12 ± 10.21 years for MDS. In both groups, over 55% are male. A total of 77.6% of patients with AML and 75% of patients with MDS received treatment prior to venetoclax. Venetoclax was administered in combination with azacitidine to 84.5% of AML and 67.5% of MDS. The relapse rate in AML is approximately 15%. Overall, the 2-year survival rate is 46% and 18.73 months. The overall CR/CRi rate for patients with AML is 49.1%, while for patients with MDS, it is 50%. The 2-year survival rate for patients with MDS is 52.7%. The 2-year RFS rate was 75.5% for AML and 90.9% for MDS. The relapse rate in AML is approximately 15%. The percentage of adverse events leading to treatment discontinuation among those with grade 3–4 toxicity is low; 26.7% for AML (n = 43) and 15% for MDS (n = 6). Conclusions: Our real-world data demonstrate that venetoclax has the potential to improve overall survival rates when used in combination with HMAs and supports its use in patients with AML/MDS.
- 12 June 2024
- Published by Nobel Tip Kitabevleri
- p. 11-24
Types of Immunotherapy, Mechanism of Action and Side Effects
Immunotherapy has emerged as a ground breaking approach in the treatment of various cancers and autoimmune diseases, utilizing the body’s immune system to combat disease. This article reviews the mechanisms of action of different types of immunotherapy, including checkpoint inhibitors, monoclonal antibodies, and adaptive cell transfer. Checkpoint inhibitors such as PD-1/PD-L1 and CTLA-4 blockers enhance immune responses by releasing brakes on T cells, thereby promoting anti-tumor immunity. Monoclonal antibodies target specific antigens on cancer cells or immune cells, facilitating targeted destruction. Adaptive cell transfer involves modifying and re-infusing patient-derived immune cells to enhance their tumor-fighting capabilities. Despite their promise, immunotherapies can elicit immune-related adverse events ranging from mild to severe, affecting various organ systems. Common side effects include fatigue, rash, and gastrointestinal disturbances, while severe reactions may involve pneumonitis, colitis, or endocrinopathies. Understanding these mechanisms and side effects is crucial for optimizing patient care and expanding the therapeutic potential of immunotherapy.
- 12 June 2024
- Published by Nobel Tip Kitabevleri
- p. 11-24
Types of Immunotherapy, Mechanism of Action and Side Effects
Immunotherapy has emerged as a ground breaking approach in the treatment of various cancers and autoimmune diseases, utilizing the body’s immune system to combat disease. This article reviews the mechanisms of action of different types of immunotherapy, including checkpoint inhibitors, monoclonal antibodies, and adaptive cell transfer. Checkpoint inhibitors such as PD-1/PD-L1 and CTLA-4 blockers enhance immune responses by releasing brakes on T cells, thereby promoting anti-tumor immunity. Monoclonal antibodies target specific antigens on cancer cells or immune cells, facilitating targeted destruction. Adaptive cell transfer involves modifying and re-infusing patient-derived immune cells to enhance their tumor-fighting capabilities. Despite their promise, immunotherapies can elicit immune-related adverse events ranging from mild to severe, affecting various organ systems. Common side effects include fatigue, rash, and gastrointestinal disturbances, while severe reactions may involve pneumonitis, colitis, or endocrinopathies. Understanding these mechanisms and side effects is crucial for optimizing patient care and expanding the therapeutic potential of immunotherapy.
- 12 June 2024
- Published by Nobel Tip Kitabevleri
- p. 33-48
Immunotherapy in Hematological Malignancy
Tumor immune tolerance represents a significant obstacle to effective cancer therapy. A multitude of pathways through which tumors evade immune surveillance have been identified . These developments have prompted a reevaluation of the "hallmarks of cancer" and have spurred the development of numerous promising immunotherapies. Various categories of immunotherapies, including stem cell transplantation, immune checkpoint inhibitors, antigen-targeted antibodies, antibody-drug conjugates, tumor vaccines, and adoptive cell therapies, have been devised for treating hematologic cancers, with ongoing clinical trials. These immunotherapies demonstrate potential for inducing long-term remissions in patients with refractory or relapsed disease, marking a paradigm shift in cancer treatment with significant clinical success. Here, we review recent advances in understanding these categories of immunotherapies for hematologic malignancies.
- 12 June 2024
- Published by Nobel Tip Kitabevleri
- p. 33-48
Immunotherapy in Hematological Malignancy
Tumor immune tolerance represents a significant obstacle to effective cancer therapy. A multitude of pathways through which tumors evade immune surveillance have been identified . These developments have prompted a reevaluation of the "hallmarks of cancer" and have spurred the development of numerous promising immunotherapies. Various categories of immunotherapies, including stem cell transplantation, immune checkpoint inhibitors, antigen-targeted antibodies, antibody-drug conjugates, tumor vaccines, and adoptive cell therapies, have been devised for treating hematologic cancers, with ongoing clinical trials. These immunotherapies demonstrate potential for inducing long-term remissions in patients with refractory or relapsed disease, marking a paradigm shift in cancer treatment with significant clinical success. Here, we review recent advances in understanding these categories of immunotherapies for hematologic malignancies.
- Open Access
- 28 December 2023
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 40 (4) , 242-250
Experience of Daratumumab in Relapsed/Refractory Multiple Myeloma: A Multicenter Study from Türkiye
This study aimed to evaluate patients with RRMM who underwent daratumumab (DARA) therapy. This multicenter and retrospective study included 134 patients who underwent at least two courses of DARA from February 01, 2018 to April 15, 2022. Epidemiologic, disease and treatment characteristics of patients and, treatment related side effects were evaluated. Survival analysis were performed. The median age at initiation of DARA therapy was 60 (35-88) years. The median time to initiation of DARA and the median follow-up time were 41.2 (5.1-223) and 5.7 (2.1-24.1) months, respectively. The ORR after DARA therapy was 75 (55.9%), and ≥VGPR was observed in 48 (35.8%) patients. Overall survival (OS) and progression-free survival (PFS) for all patients were 11.6 (7.8-15.5) and 8.0 (5.1-10.9) months, respectively. OS was higher for patients undergoing DARA-Vd than for those undergoing DARA-Rd (16.9 vs. 8.3 months; p=0.014). Among patients undergoing Dara-Rd, PFS was higher in those without EMD (EMD-) than those with EMD (EMD+)(NA vs. 3.7 months; OR, 3.4; p < 0.001). The median number of prior therapies was 3 (1-8). Initiation of DARA therapy in the early period provides OS and PFS advantage, although statistically insignificant. Infusion-related reactions were observed in 18 (13.4%) patients. All reactions occurred during the first infusion and most reactions were grade 1-2 (94.5%). The frequency of neutropenia and thrombocytopenia was higher in the DARA-Rd group (61.9% vs. 24.7%; p < 0.001 and 42.9% vs. 15.7%; p < 0.001). Our study reflects real-life data in terms of DARA therapy for patients with RRMM and supports the early initiation of DARA therapy.
- 28 December 2023
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 40 (4) , 242-250
Open AccessExperience of Daratumumab in Relapsed/Refractory Multiple Myeloma: A Multicenter Study from Türkiye
This study aimed to evaluate patients with RRMM who underwent daratumumab (DARA) therapy. This multicenter and retrospective study included 134 patients who underwent at least two courses of DARA from February 01, 2018 to April 15, 2022. Epidemiologic, disease and treatment characteristics of patients and, treatment related side effects were evaluated. Survival analysis were performed. The median age at initiation of DARA therapy was 60 (35-88) years. The median time to initiation of DARA and the median follow-up time were 41.2 (5.1-223) and 5.7 (2.1-24.1) months, respectively. The ORR after DARA therapy was 75 (55.9%), and ≥VGPR was observed in 48 (35.8%) patients. Overall survival (OS) and progression-free survival (PFS) for all patients were 11.6 (7.8-15.5) and 8.0 (5.1-10.9) months, respectively. OS was higher for patients undergoing DARA-Vd than for those undergoing DARA-Rd (16.9 vs. 8.3 months; p=0.014). Among patients undergoing Dara-Rd, PFS was higher in those without EMD (EMD-) than those with EMD (EMD+)(NA vs. 3.7 months; OR, 3.4; p < 0.001). The median number of prior therapies was 3 (1-8). Initiation of DARA therapy in the early period provides OS and PFS advantage, although statistically insignificant. Infusion-related reactions were observed in 18 (13.4%) patients. All reactions occurred during the first infusion and most reactions were grade 1-2 (94.5%). The frequency of neutropenia and thrombocytopenia was higher in the DARA-Rd group (61.9% vs. 24.7%; p < 0.001 and 42.9% vs. 15.7%; p < 0.001). Our study reflects real-life data in terms of DARA therapy for patients with RRMM and supports the early initiation of DARA therapy.
- Open Access
- 30 May 2023
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 40 (2) , 92-100
Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data
Objective: This study was undertaken to evaluate the long-term clinical efficacy of epoetin alfa and darbepoetin alfa in patients with myelodysplastic syndrome (MDS) in a real-life setting. Materials and Methods: A total of 204 patients with low-risk intermediate-1-risk MDS who received epoetin alfa or darbepoetin alfa were included. Hemoglobin levels and transfusion needs were recorded before treatment and at 12 months, 24 months, 36 months, and 48 months of treatment. Results: At the 36-month (p=0.025) and 48-month (p=0.022) visits, epoetin alfa yielded significantly higher hemoglobin levels compared to darbepoetin alfa. Transfusion needs were also significantly lower with epoetin alfa compared to darbepoetin alfa at 24 months (p=0.012) and in the low-risk group compared to the intermediate-risk group 24 months (p=0.018), 36 months (p=0.025), and 48 months (p<0.001). Treatment response rates at the 24-month, 36-month, and 48-month visits in the epoetin alfa (43.0%, 33.6%, and 27.1%), darbepoetin alfa (29.9%, 22.7%, and 16.5%), low-risk (39.3%, 30.0%, and 26.0%), and intermediate-risk (29.6%, 24.1%, and 11.1%) groups were lower than those obtained at 12 months, and the values differed significantly for the 36-month and 48-month visits with values ranging from p<0.05 to p<0.001. Conclusion: This real-life long-term ESA extension study investigated the clinical efficacy of epoetin alfa and darbepoetin alfa for up 48 months, revealing that treatment efficacy reached a plateau starting from the 24th month of therapy with a continuing decrease in treatment response rates regardless of treatment type, risk status, or gender. Nonetheless, significantly higher hemoglobin levels and marked improvement in transfusion needs were evident in epoetin- treated patients compared to darbepoetin-treated patients and in the low-risk group compared to the intermediate-risk group.
- 30 May 2023
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 40 (2) , 92-100
Open AccessLong-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data
Objective: This study was undertaken to evaluate the long-term clinical efficacy of epoetin alfa and darbepoetin alfa in patients with myelodysplastic syndrome (MDS) in a real-life setting. Materials and Methods: A total of 204 patients with low-risk intermediate-1-risk MDS who received epoetin alfa or darbepoetin alfa were included. Hemoglobin levels and transfusion needs were recorded before treatment and at 12 months, 24 months, 36 months, and 48 months of treatment. Results: At the 36-month (p=0.025) and 48-month (p=0.022) visits, epoetin alfa yielded significantly higher hemoglobin levels compared to darbepoetin alfa. Transfusion needs were also significantly lower with epoetin alfa compared to darbepoetin alfa at 24 months (p=0.012) and in the low-risk group compared to the intermediate-risk group 24 months (p=0.018), 36 months (p=0.025), and 48 months (p<0.001). Treatment response rates at the 24-month, 36-month, and 48-month visits in the epoetin alfa (43.0%, 33.6%, and 27.1%), darbepoetin alfa (29.9%, 22.7%, and 16.5%), low-risk (39.3%, 30.0%, and 26.0%), and intermediate-risk (29.6%, 24.1%, and 11.1%) groups were lower than those obtained at 12 months, and the values differed significantly for the 36-month and 48-month visits with values ranging from p<0.05 to p<0.001. Conclusion: This real-life long-term ESA extension study investigated the clinical efficacy of epoetin alfa and darbepoetin alfa for up 48 months, revealing that treatment efficacy reached a plateau starting from the 24th month of therapy with a continuing decrease in treatment response rates regardless of treatment type, risk status, or gender. Nonetheless, significantly higher hemoglobin levels and marked improvement in transfusion needs were evident in epoetin- treated patients compared to darbepoetin-treated patients and in the low-risk group compared to the intermediate-risk group.
- Open Access
- 30 April 2023
- Published by Van Yuzuncu Yil University in Van Sağlık Bilimleri Dergisi
- Vol. 16 (1) , 60-67
Non-Hodgkin Lenfoma Olgularının Geriye Dönük Değerlendirilmesi: Tek Merkez Deneyimi
AAmaç: Çalışmamızda Zonguldak Bülent Ecevit Üniversitesi Tıp Fakültesi Hematoloji Kliniğinde takip edilen 151 Non- Hodgkin lenfoma tanılı hastanın demografik verileri, tedavi yanıtları ile sağkalım analizlerinin yapılması amaçlandı. Materyal ve Metod: Non- Hodgkin lenfoma tanısı ile izlenen 151 olgunun verileri geriye dönük olarak değerlendirildi. Bulgular: Çalışmaya 151 hasta (81 kadın,70 erkek) dahil edildi. Ortanca yaş 62.6±12.9 olarak saptandı. Hastaların tanılarına bakıldığında 83(%55) hastanın diffüz büyük B hücreli lenfoma, 21(%13.9) hastanın marjinal zon lenfoma, 10(%6.6) hastanın foliküler lenfoma 26 (%17.2) hastanın mantle cell lenfoma, 9(%6.0) hastanın T hücreli lenfoma, 2(%1.3) hastanın diğer lenfoma tanısı aldığı görüldü. Hastaların 64’si tanesi ölmüş, 87 tanesi ise yaşıyor olarak saptandı. Tüm non-hodgkin lenfoma hastalarında ortalama sağ kalım süresi 64 ay iken hastalıksız sağ kalım süresi 63 ay saptandı. Sonuç: Çalışmamızda 5 yıllık sağkalım oranı literatüre göre düşük saptandı. Bunun sebebi hasta popülasyonumuzun büyük çoğunluğunun 65 yaş üstü olması, ileri evre hastalık ve komorbidite oranının yüksek olmasına bağlı olduğunu düşünüyoruz.
- 30 April 2023
- Published by Van Yuzuncu Yil University in Van Sağlık Bilimleri Dergisi
- Vol. 16 (1) , 60-67
Open AccessNon-Hodgkin Lenfoma Olgularının Geriye Dönük Değerlendirilmesi: Tek Merkez Deneyimi
AAmaç: Çalışmamızda Zonguldak Bülent Ecevit Üniversitesi Tıp Fakültesi Hematoloji Kliniğinde takip edilen 151 Non- Hodgkin lenfoma tanılı hastanın demografik verileri, tedavi yanıtları ile sağkalım analizlerinin yapılması amaçlandı. Materyal ve Metod: Non- Hodgkin lenfoma tanısı ile izlenen 151 olgunun verileri geriye dönük olarak değerlendirildi. Bulgular: Çalışmaya 151 hasta (81 kadın,70 erkek) dahil edildi. Ortanca yaş 62.6±12.9 olarak saptandı. Hastaların tanılarına bakıldığında 83(%55) hastanın diffüz büyük B hücreli lenfoma, 21(%13.9) hastanın marjinal zon lenfoma, 10(%6.6) hastanın foliküler lenfoma 26 (%17.2) hastanın mantle cell lenfoma, 9(%6.0) hastanın T hücreli lenfoma, 2(%1.3) hastanın diğer lenfoma tanısı aldığı görüldü. Hastaların 64’si tanesi ölmüş, 87 tanesi ise yaşıyor olarak saptandı. Tüm non-hodgkin lenfoma hastalarında ortalama sağ kalım süresi 64 ay iken hastalıksız sağ kalım süresi 63 ay saptandı. Sonuç: Çalışmamızda 5 yıllık sağkalım oranı literatüre göre düşük saptandı. Bunun sebebi hasta popülasyonumuzun büyük çoğunluğunun 65 yaş üstü olması, ileri evre hastalık ve komorbidite oranının yüksek olmasına bağlı olduğunu düşünüyoruz.
- Open Access
- 1 November 2022
- Published by Hematology Section, Dept. of Radiological Science and Hematology, Catholic University, Rome, Italy in Mediterranean Journal of Hematology and Infectious Diseases
- Vol. 14 (1) , e2022074
IMPACT OF COVID-19 ON OUTCOMES OF PATIENTS WITH HEMATOLOGIC MALIGNANCIES: A MULTI-CENTER, RETROSPECTIVE STUDY
Objectives: Patients with hematologic malignancies have a high risk of coronavirus disease 2019 (COVID-19) mortality. This study aimed to investigate the impact of COVID-19 on mortality rates in patients with various hematologic malignancies and to determine risk factors associated with all-cause mortality. Methods: A multi-center, observational retrospective analysis of patients with hematologic malignancies infected with COVID-19 between July 2020 and December 2021 was performed. Demographic data, clinical characteristics, and laboratory parameters were recorded. Patients were grouped as non-survivors and survivors. All-cause mortality was the primary outcome of the study. Results: There were 569 patients with a median age of 59 years. Non-Hodgkin lymphoma (22.0%) and multiple myelomas (18.1%) were the two most frequent hematologic malignancies. The all-cause mortality rate was 29.3%. The highest mortality rates were seen in patients with acute myeloid leukemia (44.3%), acute lymphoid leukemia (40.5%), and non-Hodgkin lymphoma (36.8%). The non-survivors were significantly older (p<0.001) and had more comorbidities (p<0.05). There were significantly more patients with low lymphocyte percentage (p<0.001), thrombocytopenia (p<0.001), and high CRP (p<0.001) in the non-survived patients. Cardiac comorbidities, (p=0.016), cytotoxic chemotherapy (p=0.024), low lymphocyte percentage (p=0.025), thrombocytopenia (p<0.0001), and high CRP values (p=0.017) were the independent risk factors for the prediction of mortality. Conclusions: In patients with hematologic malignancies, coexistent COVID-19 leads to a higher mortality rate in elderly patients with more comorbidities. Acute myeloid and lymphoid leukemia and non-Hodgkin lymphoma have the highest mortality rates. Cardiac diseases, cytotoxic chemotherapy, lymphopenia, thrombocytopenia, and high CRP are the independent risk factors for mortality in hematologic malignancy patients with COVID-19. Keywords: Covid; Hematologic Malignancy; Cytotoxic chemotherapy.
- 1 November 2022
- Published by Hematology Section, Dept. of Radiological Science and Hematology, Catholic University, Rome, Italy in Mediterranean Journal of Hematology and Infectious Diseases
- Vol. 14 (1) , e2022074
Open AccessIMPACT OF COVID-19 ON OUTCOMES OF PATIENTS WITH HEMATOLOGIC MALIGNANCIES: A MULTI-CENTER, RETROSPECTIVE STUDY
Objectives: Patients with hematologic malignancies have a high risk of coronavirus disease 2019 (COVID-19) mortality. This study aimed to investigate the impact of COVID-19 on mortality rates in patients with various hematologic malignancies and to determine risk factors associated with all-cause mortality. Methods: A multi-center, observational retrospective analysis of patients with hematologic malignancies infected with COVID-19 between July 2020 and December 2021 was performed. Demographic data, clinical characteristics, and laboratory parameters were recorded. Patients were grouped as non-survivors and survivors. All-cause mortality was the primary outcome of the study. Results: There were 569 patients with a median age of 59 years. Non-Hodgkin lymphoma (22.0%) and multiple myelomas (18.1%) were the two most frequent hematologic malignancies. The all-cause mortality rate was 29.3%. The highest mortality rates were seen in patients with acute myeloid leukemia (44.3%), acute lymphoid leukemia (40.5%), and non-Hodgkin lymphoma (36.8%). The non-survivors were significantly older (p<0.001) and had more comorbidities (p<0.05). There were significantly more patients with low lymphocyte percentage (p<0.001), thrombocytopenia (p<0.001), and high CRP (p<0.001) in the non-survived patients. Cardiac comorbidities, (p=0.016), cytotoxic chemotherapy (p=0.024), low lymphocyte percentage (p=0.025), thrombocytopenia (p<0.0001), and high CRP values (p=0.017) were the independent risk factors for the prediction of mortality. Conclusions: In patients with hematologic malignancies, coexistent COVID-19 leads to a higher mortality rate in elderly patients with more comorbidities. Acute myeloid and lymphoid leukemia and non-Hodgkin lymphoma have the highest mortality rates. Cardiac diseases, cytotoxic chemotherapy, lymphopenia, thrombocytopenia, and high CRP are the independent risk factors for mortality in hematologic malignancy patients with COVID-19. Keywords: Covid; Hematologic Malignancy; Cytotoxic chemotherapy.
- 20 October 2022
- Published by Konuralp Medical Journal in Konuralp Tip Dergisi
- Vol. 14 (3) , 476-480
Quadruple Therapy in Patients with Immune Thrombocytopenia
Objective:In the treatment of immune thrombocytopenia dexamethasone, rituximab, and cyclosporine combination therapies provided promising results in recent years. This study aimed to investigate the responses of patients with quadruple therapy which created by combining combinational therapies given in immune thrombocytopenia with eltrombopag. Method: Four patients diagnosed with immune thrombocytopenia who received steroid in the first-line treatment and eltrombopag in the second-line treatment without achieving complete remission/partial remission were retrospectively evaluated in terms of the treatment they received and response rates. Result:Patients with relapsed/refractory immune thrombocytopenia were treated by oral dexamethasone, oral cyclosporine and intravenous low-dose rituximab in addition to eltrombopag therapy. Eltrombopag treatment was continued at a dose of 50mg/day. No loading dose was given for cyclosporine, weekly blood cyclosporine level was monitored for toxicity and the treatment was titrated to a target dose of 200 to 400 μg/L. No toxicity-induced death, serious treatment-related adverse events, or non-adherence to treatment were observed. The 6-month response rate was 75% and the treatment was well tolerated. Two patients were still followed up by us with a complete response, while one our patient underwent splenectomy because of relapse after 6 months and is still being followed up with eltrombopag therapy. In one our patient, which was unresponsive, romiplastim treatment was applied but there was no response to this treatment either. The patient was referred to a clinical study Conclusion: Our study showing that a combination of quadruple therapy can be a treatment option in patients with treatment-resistant immune thrombocytopenia is promising.
- 20 October 2022
- Published by Konuralp Medical Journal in Konuralp Tip Dergisi
- Vol. 14 (3) , 476-480
Quadruple Therapy in Patients with Immune Thrombocytopenia
Objective:In the treatment of immune thrombocytopenia dexamethasone, rituximab, and cyclosporine combination therapies provided promising results in recent years. This study aimed to investigate the responses of patients with quadruple therapy which created by combining combinational therapies given in immune thrombocytopenia with eltrombopag. Method: Four patients diagnosed with immune thrombocytopenia who received steroid in the first-line treatment and eltrombopag in the second-line treatment without achieving complete remission/partial remission were retrospectively evaluated in terms of the treatment they received and response rates. Result:Patients with relapsed/refractory immune thrombocytopenia were treated by oral dexamethasone, oral cyclosporine and intravenous low-dose rituximab in addition to eltrombopag therapy. Eltrombopag treatment was continued at a dose of 50mg/day. No loading dose was given for cyclosporine, weekly blood cyclosporine level was monitored for toxicity and the treatment was titrated to a target dose of 200 to 400 μg/L. No toxicity-induced death, serious treatment-related adverse events, or non-adherence to treatment were observed. The 6-month response rate was 75% and the treatment was well tolerated. Two patients were still followed up by us with a complete response, while one our patient underwent splenectomy because of relapse after 6 months and is still being followed up with eltrombopag therapy. In one our patient, which was unresponsive, romiplastim treatment was applied but there was no response to this treatment either. The patient was referred to a clinical study Conclusion: Our study showing that a combination of quadruple therapy can be a treatment option in patients with treatment-resistant immune thrombocytopenia is promising.